Citadel Securities LLC recently announced the acquisition of new stake in InVivo Therapeutics Holdings Corp. (NASDAQ:NVIV). The institutional investor has increased its shareholding in the Healthcare company by 202.17% to 42794.0 shares with purchase of 28632.0 shares. This fresh investment now brings its stake to 2.24% valued currently at $0.1 million. In addition, BlackRock Fund Advisors raised its holdings by 4.0 to 34714.0 shares.
With over 0.2 million InVivo Therapeutics Holdings Corp. (NVIV) shares trading Tuesday and a closing price of $2.58 on the day, the dollar volume was approximately $0.52 million. The shares have shown a negative half year performance of -32.28% and its price on 01/24/23 gained nearly 6.17%. Currently, there are 1.91M common shares owned by the public and among those 1.91M shares have been available to trade.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 1 analysts who have offered their price forecasts for NVIV have a consensus price objective of $937.50. The analysts have set the share’s price value over the next 12 months at a high of $937.50 and a low of $937.50. But an upside of 99.72% will see the stock hit the forecast high price target while median target price for the stock is $937.50.
Insiders at the company have transacted a total of 0 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 0 of these insider trades were purchases, accounting for 0 shares. Insider sales of the common stock occurred on 0 occasions, with total insider shares sold totaling 0 shares.
The top 3 mutual fund holders in InVivo Therapeutics Holdings Corp. are Vanguard Extended Market Index Fu, Fidelity Extended Market Index Fu, and Fidelity Series Total Market Inde. Vanguard Extended Market Index Fu owns 16946.0 shares of the company’s stock, all valued at over $39823.0. Fidelity Series Total Market Inde now owns shares totaling to 0.13% of the shares outstanding.
Shares of InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) opened at $2.50, up $0.07 from a prior closing price of $2.43. However, the script later moved the day high at 2.8000, up 6.17%. The company’s stock has a 5-day price change of -1.90% and 0.00% over the past three months. NVIV shares are trading 9.79% year to date (YTD), with the 12-month market performance down to -77.81% lower. It has a 12-month low price of $1.61 and touched a high of $13.77 over the same period. NVIV has an average intraday trading volume of 84.24K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 11.81%, 18.70%, and -38.69% respectively.
Institutional ownership of InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) shares accounts for 8.60% of the company’s 1.91M shares outstanding. Mutual fund holders own 1.46%, while other institutional holders and individual stakeholders account for 7.11% and 0.06% respectively.
It has a market capitalization of $5.03M and a beta (3y monthly) value of 0.85. The earnings-per-share (ttm) stands at -$8.01. Price movements for the stock have been influenced by the stock’s volatility, which stands at 11.66% over the week and 12.70% over the month.
Analysts forecast that InVivo Therapeutics Holdings Corp. (NVIV) will achieve an EPS of $0 for the current quarter, $0 for the next quarter and $0 for 2021. The lowest estimate earnings-per-share for the quarter is $0 while analysts give the company a high EPS estimate of $0. Comparatively, EPS for the current quarter was -$210 a year ago.
Specifically, 1 Wall Street analysts polled rate the stock as a buy, while 0 of the 1 advise that investors “hold,” and 0 rated it as a “Sell.”
Ladenburg Thalmann was of a view on July 21, 2016 that the stock is Buy, while Raymond James gave the stock Strong Buy rating on July 07, 2016, issuing a price target of $13.
